Halobetasol/tazarotene explained

Halobetasol/tazarotene (Duobrii) is a topical combination drug used to treat plaque psoriasis. It combines 0.01% halobetasol propionate (a corticosteroid that reduces inflammation and suppresses the immune system) and 0.045% tazarotene (a retinoid that promotes normal skin cell turnover and has anti-inflammatory effects) in a lotion formulation.^{[1] [2] [3] [4]} It was approved as a prescription drug by the U.S. Food and Drug Administration (FDA) in April 2019^{[1] [2] [3] [4]} and by Health Canada in June 2020.^{[5] [6]}

Notes and References

1. Web site: DUOBRII- halobetasol propionate and tazarotene lotion . DailyMed . 1 January 2020 . 15 January 2024.
2. Reddy V, Myers B, Yang EJ, Bhutani T . Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults . Clinical, Cosmetic and Investigational Dermatology . 13 . 391–398 . 2020 . 32606876 . 7295208 . 10.2147/CCID.S252426. free .
3. Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R . Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology . The Journal of Dermatological Treatment . 32 . 4 . 391–398 . June 2021 . 31522563 . 10.1080/09546634.2019.1668907. 202582002 .
4. Web site: Duffy . Steve . FDA Approves Unique Combination Topical Therapy for Plaque Psoriasis . MPR . 26 April 2019 . 16 January 2024.
5. Web site: Barry . Martin . Ottawa approves Bausch Health psoriasis drug to be produced in Laval . lavalnews.ca . 15 June 2020 . 16 January 2024.
6. Web site: Voluntary compliance undertaking of Bausch Health, Canada Inc. to the Patented Medicine Prices Review Board . Government of Canada . 4 January 2023 . 16 January 2024.